Information

You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

loading
Corrigendum for Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial